- Tags: bausch and lomb
Research
Bausch + Lomb unveils 2025 state of dry eye survey results
Building on 2024 findings, latest results indicate a need for more patient education to dispel ongoing misconceptions surrounding dry eye.
Business
Bausch + Lomb names leading ophthalmologist as strategic medical advisor
Industry veteran Cathleen McCabe, MD, will consult on the company’s expanding product portfolio and serve as liaison to the global ECP community.
Products
FDA grants tentative approval for Lupin's Lumify generic eye drops
Brimonidine tartrate ophthalmic solution, 0.025% is indicated to treat ocular redness due to minor irritations in the eye.
Research
Pivotal study supports B+L's TENEO laser for myopic LASIK surgery
Pivotal 9-month study on the FDA-approved excimer laser platform reports 97.8% and 100% of eyes achieving UCDVA and CDVA of 20/25 or better.
Products
Bausch + Lomb launches enVista Aspire IOL in the US
New IOL addition to the enVista family treats lower levels of astigmatism with optimized extended range of vision.
Products
Bausch + Lomb launches LUMIFY EYE ILLUMINATIONS
Three new hypoallergenic specialty eye care products target the sensitive eye area.
Business
Bausch + Lomb adds new executives to leadership team
Roles include two vice presidents and two newly-created positions.
Products
Bausch + Lomb launches PreserVision AREDS 2 formula mini soft gels with CoQ10
Latest U.S. product rollout targets reducing the risk of moderate-to-severe AMD with heart health support.
Products
Bausch + Lomb launches Biotrue Hydration Boost CL rehydrating drops
The first and only preservative-free rehydrating drop in a multi-dose bottle is now available in the US.
Products
Bausch + Lomb launches INFUSE multifocal SiHy contact lenses in US
Daily disposable lenses target minimizing lens dryness for presbyopia patients.
Products
Bausch + Lomb launches StableVisc OVD, TotalVisc Viscoelastic System in US
New options provide cataract surgeons with dual-action protection during procedure.
Products
Bausch + Lomb receives FDA premarket approval for StableVisc OVD
Ophthalmic Viscoelastic Device to be injected via a syringe during cataract surgery to prevent tissue damage.
Business
Bausch + Lomb names new (returning) CEO
Brent Saunders will take the helm, effective March 6.
Products
FDA approves ML6710i photodynamic laser for use with Bausch + Lomb’s PDT
Photodynamic laser and therapy target treating patients with predominantly classic subfoveal choroidal neovascularization due to AMD.
Products
Bausch + Lomb releases PreserVision AREDS 2 mini soft gels with OCUSorb
The latest addition to the PreserVision AREDS lineup includes an updated formula.
Pipeline